| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6673838 | PF PRISM CV | Succinate salt of O-desmethyl-venlafaxine |
Mar, 2022
(1 year, 6 months ago) | |
| US8269040 | PF PRISM CV | Derivatives of venlafaxine and methods of preparing and using the same |
Jul, 2027
(3 years from now) | |
Pristiq is owned by Pf Prism Cv.
Pristiq contains Desvenlafaxine Succinate.
Pristiq has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Pristiq are:
- US6673838
Pristiq was authorised for market use on 29 February, 2008.
Pristiq is available in tablet, extended release;oral dosage forms.
Pristiq can be used as for the approved uses and conditions of use, including depression; maintenance treatment of major depressive disorder (mdd).
The generics of Pristiq are possible to be released after 05 July, 2027.
Drugs and Companies using DESVENLAFAXINE SUCCINATE ingredient
Market Authorisation Date: 29 February, 2008
Treatment: For the approved uses and conditions of use, including depression; Maintenance treatment of major depressive disorder (mdd)
Dosage: TABLET, EXTENDED RELEASE;ORAL
PRISTIQ family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic